Outcomes AlloMap Registry (OAR) Study


  • Heart transplant

Study Name

Outcomes AlloMap Registry (OAR) Study


The purpose of this study is to create a research registry based on heart transplant recipients. A research registry is a collection of information about patients who have a particular disease or condition, or who receive a particular treatment, to be used for future research studies. This registry will allow researchers to observe the clinical long-term management and outcomes of heart transplant recipients with the regular use of AlloMap testing.

The AlloMap blood test, which has been approved by the U.S. Food and Drug Administration, is intended to help determine if a heart transplant recipient has a low probability of acute rejection at the time of testing.

Financial disclosure: Jon Kobashigawa, MD, has a financial relationship with the sponsor of this study as follows:

  • Serves on the advisory board for the sponsor and has received payment from CareDx, Inc. in the form of a travel grant.

Inclusion Criteria

  • Heart transplant patient
  • At least 18 years of age
  • At least two months (greater than 55 days) post-transplant

Exclusion Criteria

  • Pregnancy

Principal Investigator

Jon Kobashigawa, MD

Co-Investigators Include

David Chang, MD
Jignesh Patel, MD, PhD
Michelle Kittleson, MD, PhD

Study Coordinator and Contact

Sean Sana
Phone: 310-248-7132
Email: sean.sana@cshs.org





Date Last Updated